BRIEF published on 04/15/2025 at 10:05, 8 months 3 days ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 8 months 3 days ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 8 months 3 days ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 11 months 29 days ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 11 months 29 days ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 11 months 29 days ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 3 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 3 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 3 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 12/18/2025 at 06:25, 5 hours 18 minutes ago 1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth
Published on 12/18/2025 at 00:55, 10 hours 48 minutes ago Molten Metals Corp. Announces Flow-Through Financing
Published on 12/18/2025 at 00:00, 11 hours 43 minutes ago Right Season Investments Announces Name Change to FutureGen Industries Corp.
Published on 12/17/2025 at 23:15, 12 hours 28 minutes ago Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 20 hours 43 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/18/2025 at 11:33, 9 minutes ago Notification pursuant to Article 5 para. 1 lit b), para. 3 of the Regulation (EU) No 596/2014 (MAR) Acquisition of own shares - final notice
Published on 12/18/2025 at 11:30, 13 minutes ago A Global Playground: Haier's 2026 Global Fans Festival Champions Sports, Tech, and Community
Published on 12/18/2025 at 11:00, 43 minutes ago ABB Ltd: ABB share buybacks - December 11, 2025 - December 17, 2025
Published on 12/18/2025 at 11:00, 43 minutes ago BIRKENSTOCK REPORTS FISCAL 2025 REVENUE GROWTH AHEAD OF TARGET, OUTPERFORMING ADJUSTED EBITDA AND EARNINGS GROWTH; SETS FISCAL 2026 TARGETS
Published on 12/18/2025 at 10:47, 56 minutes ago Blue Cap AG with broadened investor base: Major shareholder PartnerFonds AG i.L. publishes results of share exchange offer
Published on 12/18/2025 at 10:00, 1 hour 43 minutes ago Neoen remporte 124 MWc de projets solaires en France
Published on 12/17/2025 at 20:39, 15 hours 4 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 15 hours 4 minutes ago Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 16 hours 13 minutes ago Evolution de la composition du Conseil d’Administration
